

Data Sharing Statement

Article Info	http://dx.doi.org/10.21037/tcr-19-2899	
Item	Question	Authors' Response (place "-" if not applicable)
1	Would you like to share data collected for your study to others?	Yes
2	If not, would you like to share the reason for your decision?	-
3	What data in particular will be shared?	Primary and metastatic NPC had significantly distinct mutational signatures and mutational signaling pathways. Non-silent single nucleotide variations and Insertion–deletion mutations in CTCs were more dramatic than in primitive tumor cells.
4	Any other documents will be share?Such asstudy protocol, statistical analysis plan, informed consent form, clinical study report, analytic code.	Study protocol, informed consent form, and clinical study report will also be shared if requested.
5	When will data availability begin?	From the publication date.
6	When will data availability end?	Two years within the publication date, since the technique may be updated over time.
7	To whom will you share the data?	Clinician and researcher who are interested in the biomarkers of nasopharyngeal carcinoma.
8	For what type of analysis or purpose?	For analysis to evaluate the patterns of gene mutations in CTC of nasopharyngeal carcinoma.
9	How or where can the data/documents be obtained?	Emails could be sent to the address below to obtain the shared data: syfklxf@126.com

10	Any other restrictions?	We may balance the potential benefits and risks for each request and then provide the data that could be shared.
----	-------------------------	--